|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Poster. San Antonio Breast Cancer Symposium 2005;Abstract 2041.
Goldstein L et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/ cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc ASCO 2005;Abstract 512.
Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2006;Abstract 46.
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7 Abstract
Jones SE et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc ASCO 2003;Abstract 59.
Miller K et al. Capecitabine plus bevacizumab in first line metastatic breast cancer:
An interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. San Antonio Breast Cancer Symposium 2006;Abstract 2068.
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005a;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract
Perez EA et al. North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Poster. San Antonio Breast Cancer Symposium 2006;Abstract 2069.
 |
 |
